121 related articles for article (PubMed ID: 26848292)
1. Reduction in the level of antibodies against heat shock proteins 60 during different hormonal protocols in postmenopausal women.
Rajtar-Ciosek A; Kacalska-Janssen O; Zmaczyński A; Wyroba J; Tomczyk R; Wiatr J; Gałuszka-Bednarczyk A; Bereza T; Milewicz T; Krzysiek J
Prz Menopauzalny; 2015 Dec; 14(4):218-22. PubMed ID: 26848292
[TBL] [Abstract][Full Text] [Related]
2. [Plasma levels of total cholesterol, LDL-cholesterol, and HDL-cholesterol in postmenopausal women during 12 months' oral administration of dydrogesterone or medroxyprogesterone combined with continuous transdermal supplementation of 17beta-estradiol].
Milewicz T; Kostecka A; Rogatko I; Sztefko K; Kwiatkowska-Panek E; Radowick S; Krzysiek J
Przegl Lek; 2007; 64(2):65-9. PubMed ID: 17892034
[TBL] [Abstract][Full Text] [Related]
3. Influence of low dose oestrogen on circulating prolactin. LH and FSH levels in post-menopausal women.
Robyn C; Vekemans M
Acta Endocrinol (Copenh); 1976 Sep; 83(1):9-14. PubMed ID: 989226
[TBL] [Abstract][Full Text] [Related]
4. When is it safe to switch from oral contraceptives to hormonal replacement therapy?
Castracane VD; Gimpel T; Goldzieher JW
Contraception; 1995 Dec; 52(6):371-6. PubMed ID: 8749601
[TBL] [Abstract][Full Text] [Related]
5. Influence of modified transdermal hormone replacement therapy on the concentrations of hormones, growth factors, and bone mineral density in women with osteopenia.
Stanosz S; Zochowska E; Safranow K; Sieja K; Stanosz M
Metabolism; 2009 Jan; 58(1):1-7. PubMed ID: 19059524
[TBL] [Abstract][Full Text] [Related]
6. Effects of long-lasting raloxifene treatment on serum prolactin and gonadotropin levels in postmenopausal women.
Lasco A; Cannavò S; Gaudio A; Morabito N; Basile G; Nicita-Mauro V; Frisina N
Eur J Endocrinol; 2002 Oct; 147(4):461-5. PubMed ID: 12370106
[TBL] [Abstract][Full Text] [Related]
7. Transdermal estrogen with a levonorgestrel-releasing intrauterine device for climacteric complaints: clinical and endometrial responses.
Raudaskoski TH; Lahti EI; Kauppila AJ; Apaja-Sarkkinen MA; Laatikainen TJ
Am J Obstet Gynecol; 1995 Jan; 172(1 Pt 1):114-9. PubMed ID: 7847516
[TBL] [Abstract][Full Text] [Related]
8. The effects of compounded bioidentical transdermal hormone therapy on hemostatic, inflammatory, immune factors; cardiovascular biomarkers; quality-of-life measures; and health outcomes in perimenopausal and postmenopausal women.
Stephenson K; Neuenschwander PF; Kurdowska AK
Int J Pharm Compd; 2013; 17(1):74-85. PubMed ID: 23627249
[TBL] [Abstract][Full Text] [Related]
9. Influence of continuous combined estradiol-norethisterone acetate preparations on insulin sensitivity in postmenopausal nondiabetic women.
Kimmerle R; Heinemann L; Heise T; Bender R; Weyer C; Hirschberger S; Berger M
Menopause; 1999; 6(1):36-42. PubMed ID: 10100178
[TBL] [Abstract][Full Text] [Related]
10. Effect of chronic daily oral administration of 17 beta-oestradiol and norethisterone on the isoforms of serum gonadotrophins in post-menopausal women.
Wide L; Naessén T; Phillips DJ
Clin Endocrinol (Oxf); 1995 Jan; 42(1):59-64. PubMed ID: 7889633
[TBL] [Abstract][Full Text] [Related]
11. Comparison of continuous and sequential transdermal progestogen with sequential oral progestogen in postmenopausal women using continuous transdermal estrogen: vasomotor symptoms, bleeding patterns, and serum lipids.
Rozenberg S; Ylikorkala O; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():376-87. PubMed ID: 9397385
[TBL] [Abstract][Full Text] [Related]
12. Comparative studies of the ethynyl estrogens used in oral contraceptives. III. Effect on plasma gonadotropins.
Goldzieher JW; de la Peña A; Chenault CB; Cervantes A
Am J Obstet Gynecol; 1975 Jul; 122(5):625-36. PubMed ID: 1146928
[TBL] [Abstract][Full Text] [Related]
13. 17beta-estradiol regulation of human growth hormone (hGH), insulin-like growth factor-I (IGF-I) and insulin-like growth factor binding protein-3 (IGFBP-3) axis in hypoestrogenic, hypergonadotropic women.
Milewicz T; Krzysiek J; Sztefko K; Radowicki S; Krzyczkowska-Sendrakowska M
Endokrynol Pol; 2005; 56(6):876-82. PubMed ID: 16821205
[TBL] [Abstract][Full Text] [Related]
14. Pituitary and ovarian function in women receiving hormonal contraception.
Cohen BL; Katz M
Contraception; 1979 Nov; 20(5):475-87. PubMed ID: 393456
[TBL] [Abstract][Full Text] [Related]
15. The effect of contraceptive steroids on hypothalamic-pituitary function.
Mishell DR; Kletzky OA; Brenner PF; Roy S; Nicoloff J
Am J Obstet Gynecol; 1977 May; 128(1):60-74. PubMed ID: 403765
[TBL] [Abstract][Full Text] [Related]
16. Transdermal sequential and continuous hormone replacement regimens with estradiol and norethisterone acetate in postmenopausal women: effects on the endometrium.
Johannisson E; Holinka CF; Arrenbrecht S
Int J Fertil Womens Med; 1997; 42 Suppl 2():388-98. PubMed ID: 9397386
[TBL] [Abstract][Full Text] [Related]
17. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
[TBL] [Abstract][Full Text] [Related]
18. [Inhibition of ovulation with 35 micrograms of ethinyl estradiol and 2 mg of cyproterone acetate (Diane 35)].
Spona J; Huber J; Schmidt JB
Geburtshilfe Frauenheilkd; 1986 Jul; 46(7):435-8. PubMed ID: 3093307
[TBL] [Abstract][Full Text] [Related]
19. [Kallikrein concentration in mixed saliva after contraceptive administration or postmenopausal hormone replacement].
Meyer P; Werner E; Polzin A
Laryngorhinootologie; 1998 Sep; 77(9):521-4. PubMed ID: 9795931
[TBL] [Abstract][Full Text] [Related]
20. Differing effects of low-dose estrogen-progestin therapy and pravastatin in postmenopausal hypercholesterolemic women.
Davis SR; Goldstat R; Newman A; Berry K; Burger HG; Meredith I; Koch K
Climacteric; 2002 Dec; 5(4):341-50. PubMed ID: 12626213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
